Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients

Trial Profile

Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Feb 2016

At a glance

  • Drugs Erlotinib (Primary) ; Sunitinib (Primary)
  • Indications Gastrointestinal stromal tumours; Non-small cell lung cancer; Renal cancer
  • Focus Pharmacokinetics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Feb 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 01 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top